|
Baricitinib Clinical Trials
10 actively recruiting trials across 6 locations
No change since May 2026
Also known as: LY3009104, Olimuant, Olumiant, fluorodésoxyglucose (18F)- Positron Emission Tomography (PET)
Pipeline
Phase 1: 1Phase 2: 3Phase 3: 5
Top Sponsors
- Eli Lilly and Company4
- Emory University2
- University of Nebraska1
- National Institute of Allergy and Infectious Diseases (NIAID)1
- Galvani Bioelectronics1
Indications
- Arthritis4
- Diabetes Mellitus, Type 12
- Depression2
- Diabetes2
- Rheumatoid Arthritis2
Other3 trials
Atlanta, Georgia2 trials
Inflammation and Depression in People With HIV
Grady Memorial Hospital
Phase 2
JAK Signaling in Depression
Emory University
Phase 2
Anniston, Alabama1 trial
ConsideRAte Study - Splenic Stimulation for RA
Pinnacle Research Group, LLC
N/A
Aurora, Colorado1 trial
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Barbara Davis Center for Childhood Diabetes
Phase 3
Tallahassee, Florida1 trial
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Tallahassee Memorial HealthCare
Phase 3
Bethesda, Maryland1 trial
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
National Institutes of Health Clinical Center
Phase 1
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.